Author: Siri-Angkul, Natthaphat; Chattipakorn, Siriporn C; Chattipakorn, Nipon
Title: Angiotensin converting enzyme 2 at the interface between renin-angiotensin system inhibition and coronavirus disease 2019. Cord-id: tu921sdb Document date: 2020_7_25
ID: tu921sdb
Snippet: The coronavirus disease 2019 (COVID-19) is the third major coronavirus outbreak of this century. Its etiologic agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), requires angiotensin converting enzyme 2 (ACE2) for cellular entry. The commonly used angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are speculated to potentiate SARS-CoV-2 infectivity and worsen COVID-19 disease progression by altering ACE2 expression. Current evidence of
Document: The coronavirus disease 2019 (COVID-19) is the third major coronavirus outbreak of this century. Its etiologic agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), requires angiotensin converting enzyme 2 (ACE2) for cellular entry. The commonly used angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are speculated to potentiate SARS-CoV-2 infectivity and worsen COVID-19 disease progression by altering ACE2 expression. Current evidence of ACEI/ARB-ACE2 interaction as well as the effects of ACEIs/ARBs on viral-associated acute lung injury is summarized and discussed in this mini-review. Critical questions of translational importance that need to be addressed by further investigations are also presented. This article is protected by copyright. All rights reserved.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date